Effects of nisoldipine on cytosolic calcium, platelet aggregation, and coagulation/fibrinolysis in patients with coronary artery disease.
The effect of nisoldipine, a dihydropyridine Ca2+ antagonist, on the platelet cytosolic Ca2+ concentration ([Ca2+]i), platelet aggregation, and various coagulation and fibrinolysis parameters was assessed in normotensive patients with coronary artery disease (CAD). Eleven patients with angiographically confirmed CAD (4 men, 7 women aged 67.3 +/- 5.4 years) were administered nisoldipine at 10 mg/day for two weeks. The [Ca2+]i was determined by use of fura2-loaded platelets, platelet aggregation was measured with an aggregometer, and coagulation/fibrinolysis parameters were measured by standard methods. Nisoldipine did not significantly affect blood pressure or heart rate. However, the [Ca2+]i decreased significantly (P<0.05) and platelet aggregation was also significantly inhibited. Plasma D-dimer levels decreased significantly (P<0.01). Thus, nisoldipine not only suppressed platelet activation but also affected the coagulation system, suggesting that it is not only a vasodilator and platelet inhibitor but also an antithrombotic agent.
Fujinishi
A
A
2nd Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
Takahara
K
K
Ohba
C
C
Nakashima
Y
Y
Kuroiwa
A
A
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000368:Aged; D000990:Antithrombin III / Q000032:analysis; D001777:Blood Coagulation / Q000187:drug effects*; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D017023:Coronary Angiography; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D003600:Cytosol / Q000187:drug effects*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005456:Fluorescent Dyes; D016257:Fura-2; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D015737:Nisoldipine / Q000627:therapeutic use*; D010447:Peptide Hydrolases / Q000032:analysis; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010978:Platelet Factor 4 / Q000032:analysis; D013929:Thromboxane B2 / Q000097:blood; D010959:Tissue Plasminogen Activator / Q000097:blood; D014665:Vasodilator Agents / Q000627:therapeutic use*; D001620:beta-Thromboglobulin / Q000032:analysis
D002121:Calcium Channel Blockers; D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D005456:Fluorescent Dyes; D017395:Plasminogen Activator Inhibitor 1; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; C046193:antithrombin III-protease complex; D001620:beta-Thromboglobulin; C036309:fibrin fragment D; D010978:Platelet Factor 4; D015737:Nisoldipine; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D000990:Antithrombin III; D010447:Peptide Hydrolases; D010959:Tissue Plasminogen Activator; D002118:Calcium; D016257:Fura-2